Knowledge Library

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset of patients remains refractory to ADC treatment.  WuXi AppTec contributed to a research article which demonstrated that excessive cancer-associated fibroblasts (CAFs) can form a fibrotic barrier within a tumor microenvironment, impeding the tissue uptake of …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

BRCA2 Deficient DLD-1 Model

BRCA1 and BRCA2 proteins are key components of the homologous recombination repair pathway for repairing double-stranded DNA breaks.  Mutations in BRCA genes can significantly increase the risk of certain cancers such as breast, ovarian, pancreatic, and prostate cancer. To mimic the effects of BRCA2 deficiency in humans, WuXi Biology has constructed a BRCA2 deficient mouse …Read More >

Resource Type: Presentation
Resource Topic: Oncology, Tumor Models

VIEW

PRMT5 Related Tumor Models

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in approximately 10 – 15% of all human cancers. When the MTAP gene is deleted, methylthioadenosine (MTA) accumulates and selectively inhibits PRMT5. This creates a synthetic lethal dependence on PRMT5 in MTAP-deleted tumors. As a potential …Read More >

Resource Type: Presentation
Resource Topic: Oncology, Tumor Models

VIEW

Developing Novel AR Mutant Prostate Cancer Models

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key therapeutic strategy for treating advanced metastatic prostate cancer. While AR antagonists like enzalutamide can significantly improve survival in prostate cancer patients, resistance often develops over time, largely driven by treatment-induced mutations within the ligand-binding domain …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Oncology, Tumor Models

VIEW

BTK Inhibitor-Resistant Lymphoma Animal Models

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, …Read More >

Resource Type: Presentation
Resource Topic: Oncology, Tumor Models

VIEW

Oncogenic Virus-associated Tumor Models

Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily from viruses like HPV, EBV, HBV, and HCV. The innate and adaptive immune systems play important roles in oncogenic viral infection and subsequent cancer development. As viral cancers have viral-specific targets and biomarkers, there is …Read More >

Resource Type: Presentation
Resource Topic: Infectious Diseases, Oncology, Tumor Models

VIEW

OncoWuXi Express: PDX Panel Service

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share our newly launched PDX panel service with you. https://onco.wuxiapptec.com Introduction: Patient-derived xenograft (PDX) models are generated by implanting …Read More >

Resource Type: Article, Blog
Resource Topic: Oncology, Tumor Models

VIEW

USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven Anti-Cancer Activity

Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation by the proteasome. USP7 activity has been implicated in cancer progression and its overexpression is associated with tumor aggressiveness and poor prognosis in a variety of cancer types, making USP7 inhibition an attractive strategy for …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Cell-based Assays, Oncology, Structural Biology, Targeted Protein Degradation, Tumor Models

VIEW

Paclitaxel-Induced Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. WuXi Biology has established gastric cancer and breast cancer cell lines that …Read More >

Resource Type: Video
Resource Topic: Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!